The independent source for health policy research, polling, and news.
721 - 740 of 806 Results
Donald Trump accepted his party's nomination to seek reelection for a second term as president in front of a partisan audience that appeared to largely lack masks and opt against social distancing.
A robust sign-up for flu shots could help head off a nightmare scenario in the coming winter of hospitals stuffed with both COVID-19 patients and those suffering from severe effects of influenza. Plus, no one knows how flu and COVID might interact if a patient got both.
Harbor-UCLA Medical Center serves patients who are especially vulnerable to the coronavirus: They are essential workers, have chronic diseases and are members of underrepresented racial and ethnic groups. When the safety-net hospital kicks off enrollment for its COVID-19 vaccine trial Wednesday, it will look to those patients to participate.
Advocates of cheap and widely available vaccines thought the pandemic might change business as usual. They were wrong.
Polio terrified Americans, and in 1955, when Jonas Salk鈥檚 vaccine became available, they snapped it up like candy. Sixty-five years later, COVID is the latest dread virus, but many undercurrents could inhibit its acceptance.
A small allergy clinic in Medford, Oregon, might seem an unlikely place to recruit hundreds of volunteers to test the Moderna vaccine against COVID-19. But its steward has a record of leading hundreds of clinical trials.
People have flooded U.S. testing sites with requests to participate in the pivotal, late-stage clinical trials of the first two COVID-19 vaccine candidates.
Vaccines engineered to protect the public from influenza, hepatitis B, tetanus and rabies are less effective for obese people, leaving them more vulnerable to serious illness. As scientists race to develop a COVID-19 vaccine, experts say obesity could prove an impediment 鈥 a sobering prospect for a nation in which nearly half of all adults are obese.
Teams are starting to test vaccines using messenger RNA or chimpanzee cold viruses to inoculate humans. Will their benefits last?
President Donald Trump鈥檚 sobering view of COVID-19 didn鈥檛 last long 鈥 this week, he was back to pushing hydroxychloroquine, a drug that has been shown not to work in treating the virus. Meanwhile, Republicans on Capitol Hill are still scrambling to agree among themselves and with the White House on the next coronavirus relief bill, as both a moratorium on evictions and extra unemployment payments expire. And the debate over drug prices, which was going to be one of the biggest health issues of this election year, makes a brief appearance. Alice Miranda Ollstein of Politico, Mary Ellen McIntire of CQ Roll Call and Anna Edney of Bloomberg News join KHN鈥檚 Julie Rovner to discuss this and more. Also, Rovner interviews KHN鈥檚 Markian Hawryluk, who wrote the latest KHN-NPR 鈥淏ill of the Month鈥 story about a surprise bill from a surprise surgical assistant.
The FDA must approve any coronavirus vaccine before it鈥檚 widely distributed, but political pressure could cloud the decision.
Under ordinary circumstances, these phases of vaccine development can take years to complete. But now, during the age of coronavirus, the timeline is being shortened. Here's an inventory of where things stand.
A federal study finds 35% of people 60 and older were vaccinated for shingles by 2018, up from 7% in 2008, but low-income people and those who are Black or Hispanic are far less likely to get vaccinated.
The United States is the only developed nation unable to balance cost, efficacy and social good in setting prices.
Easy-breezy guest writer Rachel Bluth fills you in on a healthy dose of news from this past week.
The Trump administration rolled back protections for transgender patients just days before the Supreme Court cemented LGBTQ rights under the Civil Rights Act. So, what now? Meanwhile, coronavirus politics reaches beyond health care settings. Anna Edney of Bloomberg News, Tami Luhby of CNN and Shefali Luthra of KHN join KHN鈥檚 Julie Rovner to discuss this and more. Also, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
KHN senior correspondent Jordan Rau spins through this week鈥檚 essential health care news.
KHN executive editor Damon Darlin wades through mounds of health care policy stories 鈥 so you don鈥檛 have to.
Just about every state is lifting some coronavirus-related restrictions, but it鈥檚 unclear how things are really going, considering data on the spread of the virus lags and may not be reliable. Meanwhile, the federal government continues to throw more responsibility for dealing with the pandemic to state and local governments. Margot Sanger-Katz of The New York Times, Kimberly Leonard of Business Insider and Alice Miranda Ollstein of Politico join KHN鈥檚 Julie Rovner to discuss this and more.
Trials are an immense undertaking involving tens of thousands of participants. They鈥檙e likely to start this summer 鈥 but don鈥檛 expect quick results. And what鈥檚 a successful result, anyway?
漏 2026 KFF